RESUMO A hemiparesia e a espasticidade são consequências comuns em pacientes que sofreram um acidente vascular cerebral (AVC) e delas decorre a dificuldade do paciente de movimentar o hemicorpo acometido. O objetivo deste estudo foi, assim, verificar a relação da espasticidade no membro superior (MS) com a capacidade de movimentação da mão desses pacientes, a partir de um estudo transversal de delineamento ex-post facto correlacional. Foram avaliados pacientes que realizavam acompanhamento no Ambulatório Neurovascular do Hospital de Clínicas de Porto Alegre (HCPA). Foi preenchida uma ficha de avaliação com dados da amostra e realizada a avaliação da espasticidade do MS, por meio da escala de Ashworth modificada (MAS), e da movimentação ativa da mão, por meio da escala de movimentação da mão (EMM). Para a correlação das variáveis, foi usado o coeficiente de correlação tau de Kendall, adotando-se um nível de significação de 5% (p≤0,05). Foram avaliados 47 sujeitos de ambos os sexos com média de idade de 64,5 (±13) anos e média de tempo de AVC de 2,7 (±1,8) meses. A moda da EMM foi de 6 pontos e 74,4% dos pacientes não eram espásticos. O movimento da mão apresentou correlação significativa negativa com as musculaturas espásticas avaliadas. Houve uma correlação negativa moderada com as musculaturas peitoral (r=−0,383; p=0,007), os flexores de cotovelo (r=−0,339; p=0,016) e pronadores (r=−0,460; p=0,001), e correlação negativa alta com os flexores de punho (r=−0,588; p<0,001) e os flexores de dedos (r=−0,692; p<0,001). Concluiu-se que quanto maior o grau de espasticidade do membro superior, menor a capacidade de movimentação da mão dos pacientes.

Hemiparesis and spasticity are common consequences in stroke patients, hampering the movement in the affected side. Our study aimed to correlate upper limb spasticity and the ability to move the hand in these patients. This is a quantitative cross-sectional study with an ex post facto correlational design. We evaluated patients undergoing follow-up at the Neurovascular Outpatient Clinic at the Hospital de Clínicas de Porto Alegre. An evaluation form was filled out with sample data and the upper limb spasticity was evaluated using the Modified Ashworth Scale and the active hand movement using the Hand Movement Scale. Correlation of variables were verified using Kendall’s rank correlation coefficient. A significance level of 5% (p≤0.05) was adopted. In total, we evaluated 47 subjects of all genders, with a mean age of 64.5 (±13) years and a mean stroke time of 2.7 (±1.8) months. The Hand movement Scale mode was 6 points, and 74.4% of patients were not spastic. Hand movement showed a significant negative correlation with the spastic muscles evaluated. There was a moderate negative correlation with the pectoral muscles (r=−0.383; p=0.007), elbow flexors (r=−0.339; p=0.016) and pronators (r=−0.460; p=0.001) and high negative correlation with wrist flexors (r=−0.588; p<0.001) and finger flexors (r=−0.692; p<.001). The greater the degree of spasticity of the upper limb, the smaller the hand movement capacity in stroke patients.

Background: Spasticity, fatigue, muscle weakness and changes in gait are some of the main motor symptoms of Multiple Sclerosis (MS). These changes can interfere with the patients’ quality of life. Objective: To characterize the motor and quality of life symptoms in patients with relapsing-remitting Multiple Sclerosis at a specialized center. Methods: Fifty five patients at the Neuroimmunology Outpatient Clinic of the Hospital de Clínicas de Porto Alegre were evaluated for fatigue (Fatigue Severity Scale — FSS), walking ability (Functional Ambulation Categories — FAC), impact of MS on walking (Multiple Sclerosis Walking Scale-12 — MSWS-12), walking speed (10-Meter Walk Test — 10MWT and the Times 25-foot Walk test — T25FW), functional independence (Barthel Index — BI), functional mobility (Timed Up and Go — TUG), and quality of life (Multiple Sclerosis Impact Scale — MSIS-29). Results: The patients were mostly women (69.1%), with average age of 43.3 (±12.1) years old, with time since diagnosis of 8.2 (±5.3) years, and EDSS average of 4.3 (±1.3). On the BI, the mean was 96.6 (±5.7) points and 80% of the patients had FAC 5. At MSIS-29, patients had a higher average score on the psychological scale (19.5±26.7) than on the physical scale (10.2±23.6). Most patients (69.1%) presented fatigue. Conclusion: The patients had preserved functional independence and functional walking ability and presence of fatigue. There was minimal impact of MS on patients’ quality of life.

Devastating or nearly invariably fatal infections caused by free-living amoebae (FLA), including Acanthamoeba keratitis (AK), granulomatous amoebic encephalitis (GAE), and primary amoebic meningoencephalitis (PAM), remain a significant public health concern, driven by increasing case numbers, geographic expansion, and the lack of approved, effective, and safe treatments. Despite decades of research, no new drugs have been successfully approved, highlighting the severe limitations of de novo drug development for these infections, particularly for GAE and PAM, largely due to the challenges of conducting clinical trials for these rare and rapidly lethal diseases. In this context, drug repurposing represents a cost-effective and promising strategy to accelerate therapeutic advances and overcome key bottlenecks of conventional drug development. Accordingly, we conducted a systematic review of in vitro studies and animal models of AK, GAE, and PAM reported in indexed databases to identify promising drug repurposing candidates against FLA infections. After screening 23,624 records, 112 studies were included in the analysis. Overall, 2726 drugs and drug combinations, spanning 865 pharmacological classes and approved for 565 therapeutic indications, were assessed for their repurposing potential. Among these, 166 compounds showed substantial trophocidal activity (≥IC₅₀) at potentially translatable concentrations (≤10 µM), including six with additional cysticidal activity. In vitro, four compounds were active against Balamuthia mandrillaris, 44 against Acanthamoeba spp. (three cysticidal), and 115 against Naegleria spp. (three cysticidal). In in vivo studies, sulfadiazine and rifampicin were effective as preventive or early monotherapies for GAE. For AK, the combination of polyhexamethylene biguanide, neomycin, and atropine, as well as voriconazole and nitazoxanide monotherapies, showed the greatest promise. In PAM, azithromycin alone or in combination with amphotericin B emerged as the most promising therapeutic options. Further studies are required to advance the clinical translatability of these findings. To the best of our knowledge, this work provides the first comprehensive and integrated synthesis of repurposable drug candidates against FLA infections.